$45 Billion Biosimilar Wake-Up Call
f you don’t control your biosimilar strategy, your PBM will — and you’ll still be paying brand-name prices for generic drugs.
Employer health plan strategy, benefits design, healthcare spending, and outcomes for employees and their families.
f you don’t control your biosimilar strategy, your PBM will — and you’ll still be paying brand-name prices for generic drugs.
From Frustration to Fix: The PBM Field Guide We’re putting PBM procurement back in the hands of fiduciaries at RosettaFest Executive Brief Two Big Moments. One…
The Contract That Protects or Betrays When Fiduciary Duty Meets Contract Fine Print Most contracts protect the drafter. Healthcare vendor contracts go one step further: they…
Popular Doesn’t Mean Prudent The Hidden Risks of Voluntary Benefits—and the Fiduciary Blind Spot Letting It Happen Voluntary benefits may seem harmless—low-cost perks offered without employer…
When Five-Figure Pills Deliver Three-Week Benefits, Fiduciaries Must Intervene
What Health Plans Haven’t Yet Learned from 401(k)s Same law. Same risks. Bigger blind spots. Executive Brief The fiduciary failures we fixed in retirement plans are…
What I Learned from 25 Newsletters And a Lot of Lawsuits Executive Brief Welcome to Issue #26 of The Health Plan Compliance Advantage. Most newsletters don’t…
Is Your Health Plan Killing the Corner Pharmacy? How employer decisions fuel pharmacy closures—and what you can do about it Executive Brief Independent pharmacies are disappearing—hurting…
Employers Say They Put People First Until Someone Gets Sick When that spreadsheet-driven plan design causes delays, denials, or dropped coverage, it’s not just a bad…
Rising Risk of Pharmacy Benefits Board Directors Are Now Named Defendants Recent lawsuits against major corporations highlight a growing risk: PBM mismanagement is leading to overspending,…